WallStSmart

ResMed Inc (RMD)vsSandisk Corp (SNDK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sandisk Corp generates 65% more annual revenue ($8.93B vs $5.40B). RMD leads profitability with a 27.5% profit margin vs -11.7%. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

SNDK

Hold

49

out of 100

Grade: D+

Growth: 7.3Profit: 5.0Value: 5.0Quality: 8.0
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.3%)

Margin of Safety

+14.3%

Fair Value

$303.00

Current Price

$225.99

$77.01 discount

UndervaluedFair: $303.00Overvalued

Intrinsic value data unavailable for SNDK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

SNDK5 strengths · Avg: 9.8/10
Operating MarginProfitability
35.5%10/10

Strong operational efficiency at 35.5%

Revenue GrowthGrowth
61.2%10/10

Revenue surging 61.2% year-over-year

EPS GrowthGrowth
618.0%10/10

Earnings expanding 618.0% YoY

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Market CapQuality
$104.75B9/10

Large-cap with strong market position

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

SNDK4 concerns · Avg: 2.8/10
Price/BookValuation
10.3x4/10

Trading at 10.3x book value

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
-9.4%2/10

ROE of -9.4% — below average capital efficiency

Profit MarginProfitability
-11.7%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : SNDK

The strongest argument for SNDK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 61.2% demonstrates continued momentum.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : SNDK

The primary concerns for SNDK are Price/Book, Altman Z-Score, Return on Equity.

Key Dynamics to Monitor

RMD profiles as a mature stock while SNDK is a hypergrowth play — different risk/reward profiles.

SNDK is growing revenue faster at 61.2% — sustainability is the question.

SNDK generates stronger free cash flow (980M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (70/100 vs 49/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Sandisk Corp

TECHNOLOGY · COMPUTER HARDWARE · USA

Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.

Visit Website →

Want to dig deeper into these stocks?